drug
as of 2026-07-01Elpipodect
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Merck Sharp & Dohme LLC
6 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
6
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
NCT04624243Phase 2Completed
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
NCT05893862Phase 1Completed
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
NCT05406440Phase 1Completed
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
NCT04506905Phase 1Completed
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
NCT03055338Phase 2Completed
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
NCT02181803Phase 1Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication